• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BOT
Click for more information
2.86% 34.0¢

BOTANIX PHARMACEUTICALS LTD - Announcements

Market Cap $707.4M  ! watchlist Created with Sketch. Add to my watchlist

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is... Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BOT Appendix 4G and Corporate Governance Statement19/09/24
BOT Annual Report19/09/24
BOT BOT antimicrobial data presented at ASM-ESCMID Conference06/09/19
BOT Appendix 3B and Notice Under Section 708A18/03/19
BOT Details of Company Address13/03/19
BOT Updated Investor Presentation04/03/19
BOT Opinion Leaders Present Botanix Data at AAD 201904/03/19
BOT Appendix 3B28/02/19
BOT Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
BOT Permetrex Outperforms Other CBD Topical ProductsPRICE SENSITIVE26/02/19
BOT Change of Director's Interest Notice SW26/02/19
BOT Appendix 3B22/02/19
BOT Initial Director's Interest Notice SW21/02/19
BOT Appointment of Non-Executive Chairman Dr Stewart Washer21/02/19
BOT Initial Director's Interest Notice MT15/02/19
BOT Appointment of Executive Director Dr Michael Thurn12/02/19
BOT Final Director's Interest Notice11/02/19
BOT Passing of Non-Executive Chairman Mr Graham Griffiths08/02/19
BOT 2019 Outlook Presentation31/01/19
BOT Appendix 4C - QuarterlyPRICE SENSITIVE31/01/19
BOT Investigators Meeting Completed for BTX 1204 Phase 2 StudyPRICE SENSITIVE25/01/19
BOT Ethics Approval for Phase 2 Atopic Dermatitis Study ReceivedPRICE SENSITIVE18/12/18
BOT Botanix Presents at International Cannabinoid Summit14/12/18
BOT Appendix 3B06/12/18
BOT Investor Presentation05/12/18
BOT Botanix receives A$4.6m R&D Tax Incentive refundPRICE SENSITIVE23/11/18
BOT Results of Meeting19/11/18
BOT Annual General Meeting Chairmans Address19/11/18
BOT Investor Presentation15/11/18
BOT First Patient Treated in BTX 1308 Psoriasis Patient StudyPRICE SENSITIVE07/11/18
BOT Appendix 4C - QuarterlyPRICE SENSITIVE31/10/18
BOT Notice of Annual General Meeting/Proxy Form19/10/18
BOT Botanix Presents at Fall Clinical Dermatology Conference19/10/18
BOT Ethics Approval for BTX 1308 Psoriasis Patient Study SecuredPRICE SENSITIVE27/09/18
BOT Appendix 4G21/09/18
BOT Annual Report to shareholders21/09/18
BOT Botanix presents at European Dermatology Conference13/09/18
BOT Botanix BTX 1503 Clinical Trial UpdatePRICE SENSITIVE12/09/18
BOT Pause in tradingPRICE SENSITIVE12/09/18
BOT Preliminary Final ReportPRICE SENSITIVE31/08/18
BOT FDA Clears Development Path for BTX 1204PRICE SENSITIVE30/08/18
BOT Updated Investor Presentation Revised13/08/18
BOT Updated Investor Presentation13/08/18
BOT Appendix 4C - QuarterlyPRICE SENSITIVE31/07/18
BOT Botanix Expands Clinical Capabilities27/07/18
BOT Investigators Meeting Completed for BTX 1503 Phase 2 TrialPRICE SENSITIVE23/07/18
BOT Botanix Joins with UQ to Accelerate Development of BTX 1801PRICE SENSITIVE19/07/18
BOT Appendix 3B16/07/18
BOT Botanix update on development pipeline productsPRICE SENSITIVE02/07/18
BOT Release of Securities from Escrow29/06/18
BOT Change in substantial holding27/06/18
BOT Change in substantial holding27/06/18
BOT Completion of Placement27/06/18
BOT Appendix 3B and Notice Under Section 708A27/06/18
BOT First Patients Recruited into BTX 1503 Phase 2 Acne TrialPRICE SENSITIVE27/06/18
BOT BOT Welcomes First FDA Approval for Cannabidiol ProductPRICE SENSITIVE26/06/18
BOT Botanix Raises A$8m in Oversubscribed PlacementPRICE SENSITIVE20/06/18
BOT Trading HaltPRICE SENSITIVE18/06/18
BOT Australian Ethics approval for Acne StudyPRICE SENSITIVE13/06/18
BOT Investor Presentation12/06/18
BOT BTX 1204 Atopic Dermatitis Study Results PresentationPRICE SENSITIVE07/06/18
BOT Botanix Announces Successful Atopic Dermatitis Study ResultsPRICE SENSITIVE06/06/18
BOT Trading HaltPRICE SENSITIVE05/06/18
BOT Presentation on Atopic Dermatitis MarketPRICE SENSITIVE23/05/18
BOT BOT Presents BTX 1503 Data at International Dermatology Meet18/05/18
BOT Results of Meeting11/05/18
BOT Appendix 3B and Notice Under Section 708A09/05/18
BOT FDA Green Light for BTX 1503 Phase 2 StudyPRICE SENSITIVE08/05/18
BOT Change of Director's Interest Notice * 401/05/18
BOT Appendix 4C - quarterlyPRICE SENSITIVE24/04/18
BOT Notice of General Meeting/Proxy Form12/04/18
BOT Investor Presentation09/04/18
BOT Enrolment of BTX 1204 Atopic Dermatitis Study CompletedPRICE SENSITIVE09/04/18
BOT Half Yearly Report and AccountsPRICE SENSITIVE26/02/18
BOT American Academy of Dermatology Annual Meeting Presentation15/02/18
BOT Change in substantial holding14/02/18
BOT Change in substantial holding14/02/18
BOT Appendix 3B and Notice Under Section 708A12/02/18
BOT Completion of PlacementPRICE SENSITIVE12/02/18
BOT Appendix 3B and Notice Under Section 708A07/02/18
BOT Investor Presentation05/02/18
BOT Significantly Oversubscribed A$15m PlacementPRICE SENSITIVE05/02/18
BOT Trading HaltPRICE SENSITIVE01/02/18
BOT Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
BOT Botanix Announces Successful Acne Study ResultsPRICE SENSITIVE29/01/18
BOT Trading HaltPRICE SENSITIVE24/01/18
BOT Presentation to Botanix Advisory Board22/01/18
BOT Botanix Receives A$1.6m R&D Tax Incentive RefundPRICE SENSITIVE16/01/18
BOT Botanix Presents at San Francisco Dermatology Summit08/01/18
BOT Botanix Completes Enrolment of BTX 1503 Acne Patient StudyPRICE SENSITIVE18/12/17
BOT Botanix BTX 1204 Study featured on 7News07/12/17
BOT New Antibacterial Results Support BTX 1503 Acne ProgramPRICE SENSITIVE05/12/17
BOT Botanix Enrols First Patients in Dermatitis StudyPRICE SENSITIVE23/11/17
BOT Results of Meeting14/11/17
BOT 2017 Annual General Meeting Chairmans Address14/11/17
BOT Investor Presentation13/11/17
BOT Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
BOT Botanix Commences BTX 1204 Dermatitis Patient StudyPRICE SENSITIVE31/10/17
BOT Notice of Annual General Meeting/Proxy Form13/10/17
BOT FDA Clears Development Path for BTX 1503PRICE SENSITIVE09/10/17
BOT Appendix 4G and Corporate Governance Statement
19/09/24
BOT Annual Report
19/09/24
BOT BOT antimicrobial data presented at ASM-ESCMID Conference
06/09/19
BOT Appendix 3B and Notice Under Section 708A
18/03/19
BOT Details of Company Address
13/03/19
BOT Updated Investor Presentation
04/03/19
BOT Opinion Leaders Present Botanix Data at AAD 2019
04/03/19
BOT Appendix 3B
28/02/19
BOT Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
BOT Permetrex Outperforms Other CBD Topical Products
26/02/19PRICE SENSITIVE
BOT Change of Director's Interest Notice SW
26/02/19
BOT Appendix 3B
22/02/19
BOT Initial Director's Interest Notice SW
21/02/19
BOT Appointment of Non-Executive Chairman Dr Stewart Washer
21/02/19
BOT Initial Director's Interest Notice MT
15/02/19
BOT Appointment of Executive Director Dr Michael Thurn
12/02/19
BOT Final Director's Interest Notice
11/02/19
BOT Passing of Non-Executive Chairman Mr Graham Griffiths
08/02/19
BOT 2019 Outlook Presentation
31/01/19
BOT Appendix 4C - Quarterly
31/01/19PRICE SENSITIVE
BOT Investigators Meeting Completed for BTX 1204 Phase 2 Study
25/01/19PRICE SENSITIVE
BOT Ethics Approval for Phase 2 Atopic Dermatitis Study Received
18/12/18PRICE SENSITIVE
BOT Botanix Presents at International Cannabinoid Summit
14/12/18
BOT Appendix 3B
06/12/18
BOT Investor Presentation
05/12/18
BOT Botanix receives A$4.6m R&D Tax Incentive refund
23/11/18PRICE SENSITIVE
BOT Results of Meeting
19/11/18
BOT Annual General Meeting Chairmans Address
19/11/18
BOT Investor Presentation
15/11/18
BOT First Patient Treated in BTX 1308 Psoriasis Patient Study
07/11/18PRICE SENSITIVE
BOT Appendix 4C - Quarterly
31/10/18PRICE SENSITIVE
BOT Notice of Annual General Meeting/Proxy Form
19/10/18
BOT Botanix Presents at Fall Clinical Dermatology Conference
19/10/18
BOT Ethics Approval for BTX 1308 Psoriasis Patient Study Secured
27/09/18PRICE SENSITIVE
BOT Appendix 4G
21/09/18
BOT Annual Report to shareholders
21/09/18
BOT Botanix presents at European Dermatology Conference
13/09/18
BOT Botanix BTX 1503 Clinical Trial Update
12/09/18PRICE SENSITIVE
BOT Pause in trading
12/09/18PRICE SENSITIVE
BOT Preliminary Final Report
31/08/18PRICE SENSITIVE
BOT FDA Clears Development Path for BTX 1204
30/08/18PRICE SENSITIVE
BOT Updated Investor Presentation Revised
13/08/18
BOT Updated Investor Presentation
13/08/18
BOT Appendix 4C - Quarterly
31/07/18PRICE SENSITIVE
BOT Botanix Expands Clinical Capabilities
27/07/18
BOT Investigators Meeting Completed for BTX 1503 Phase 2 Trial
23/07/18PRICE SENSITIVE
BOT Botanix Joins with UQ to Accelerate Development of BTX 1801
19/07/18PRICE SENSITIVE
BOT Appendix 3B
16/07/18
BOT Botanix update on development pipeline products
02/07/18PRICE SENSITIVE
BOT Release of Securities from Escrow
29/06/18
BOT Change in substantial holding
27/06/18
BOT Change in substantial holding
27/06/18
BOT Completion of Placement
27/06/18
BOT Appendix 3B and Notice Under Section 708A
27/06/18
BOT First Patients Recruited into BTX 1503 Phase 2 Acne Trial
27/06/18PRICE SENSITIVE
BOT BOT Welcomes First FDA Approval for Cannabidiol Product
26/06/18PRICE SENSITIVE
BOT Botanix Raises A$8m in Oversubscribed Placement
20/06/18PRICE SENSITIVE
BOT Trading Halt
18/06/18PRICE SENSITIVE
BOT Australian Ethics approval for Acne Study
13/06/18PRICE SENSITIVE
BOT Investor Presentation
12/06/18
BOT BTX 1204 Atopic Dermatitis Study Results Presentation
07/06/18PRICE SENSITIVE
BOT Botanix Announces Successful Atopic Dermatitis Study Results
06/06/18PRICE SENSITIVE
BOT Trading Halt
05/06/18PRICE SENSITIVE
BOT Presentation on Atopic Dermatitis Market
23/05/18PRICE SENSITIVE
BOT BOT Presents BTX 1503 Data at International Dermatology Meet
18/05/18
BOT Results of Meeting
11/05/18
BOT Appendix 3B and Notice Under Section 708A
09/05/18
BOT FDA Green Light for BTX 1503 Phase 2 Study
08/05/18PRICE SENSITIVE
BOT Change of Director's Interest Notice * 4
01/05/18
BOT Appendix 4C - quarterly
24/04/18PRICE SENSITIVE
BOT Notice of General Meeting/Proxy Form
12/04/18
BOT Investor Presentation
09/04/18
BOT Enrolment of BTX 1204 Atopic Dermatitis Study Completed
09/04/18PRICE SENSITIVE
BOT Half Yearly Report and Accounts
26/02/18PRICE SENSITIVE
BOT American Academy of Dermatology Annual Meeting Presentation
15/02/18
BOT Change in substantial holding
14/02/18
BOT Change in substantial holding
14/02/18
BOT Appendix 3B and Notice Under Section 708A
12/02/18
BOT Completion of Placement
12/02/18PRICE SENSITIVE
BOT Appendix 3B and Notice Under Section 708A
07/02/18
BOT Investor Presentation
05/02/18
BOT Significantly Oversubscribed A$15m Placement
05/02/18PRICE SENSITIVE
BOT Trading Halt
01/02/18PRICE SENSITIVE
BOT Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
BOT Botanix Announces Successful Acne Study Results
29/01/18PRICE SENSITIVE
BOT Trading Halt
24/01/18PRICE SENSITIVE
BOT Presentation to Botanix Advisory Board
22/01/18
BOT Botanix Receives A$1.6m R&D Tax Incentive Refund
16/01/18PRICE SENSITIVE
BOT Botanix Presents at San Francisco Dermatology Summit
08/01/18
BOT Botanix Completes Enrolment of BTX 1503 Acne Patient Study
18/12/17PRICE SENSITIVE
BOT Botanix BTX 1204 Study featured on 7News
07/12/17
BOT New Antibacterial Results Support BTX 1503 Acne Program
05/12/17PRICE SENSITIVE
BOT Botanix Enrols First Patients in Dermatitis Study
23/11/17PRICE SENSITIVE
BOT Results of Meeting
14/11/17
BOT 2017 Annual General Meeting Chairmans Address
14/11/17
BOT Investor Presentation
13/11/17
BOT Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
BOT Botanix Commences BTX 1204 Dermatitis Patient Study
31/10/17PRICE SENSITIVE
BOT Notice of Annual General Meeting/Proxy Form
13/10/17
BOT FDA Clears Development Path for BTX 1503
09/10/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
34.0¢ 		Change
-0.010(2.86%) 		Mkt cap ! $707.4M
Open High Low Value Volume
34.0¢ 34.5¢ 33.5¢ $588.0K 1.730M

Buyers (Bids)

No. Vol. Price($)
1 2571 34.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.5¢ 138117 5
View Market Depth
Last trade - 16.10pm 03/12/2024 (20 minute delay) ?
Last
34.3¢ 		  Change
-0.010 ( 0.70 %)
Open High Low Volume
34.3¢ 34.5¢ 34.0¢ 801511
Last updated 15.59pm 03/12/2024 ?
BOT (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.